<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866695</url>
  </required_header>
  <id_info>
    <org_study_id>Leo AK</org_study_id>
    <nct_id>NCT02866695</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients</brief_title>
  <official_title>Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid
      organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney
      transplant recipients and 10 lung transplant recipients. The investigators have selected
      these two populations as the represent the spectrum of solid organ transplantation: kidney
      transplant recipients are the largest transplant population, but have lower levels of
      immunosuppression and skin cancer risk. Lung transplant recipients have the highest burden of
      skin cancer and actinic keratoses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratoses (AK) are patches of dysplastic keratinocytes arising in sun-damaged skin.
      These lesions are precursors to cutaneous squamous cell carcinoma (SCC), and are treated to
      prevent progression to SCC. First-line therapy for AK include cryotherapy and curettage,
      which target clinically visible lesions but do not address the subclinical lesions in the
      field of ultraviolet radiation damage. Field therapy includes topical chemotherapy,
      immunotherapy, and photodynamic therapy. Ingenol mebutate is the active compound found in
      Euphorbia peplus sap, and has been approved for treatment of AK in immunocompetent patients.
      Ingenol mebutate 0.015% is favored over other topical treatments for treatment of AK on the
      face due to the brief treatment course, high clearance rate, and resolution without sequelae.

      Solid organ transplant recipients (OTR) have a high incidence of AK and high risk of
      developing SCC, and require frequent field therapy. In addition, OTR generally have a higher
      burden of AK and require treatment of a larger surface area than the 25 cm2 area labeled for
      ingenol mebutate 0.015%. The investigators plan to investigate the safety and efficacy of
      ingenol mebutate 0.015% in OTR, with a treatment area up to 100cm2.

      This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid
      organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney
      transplant recipients and 10 lung transplant recipients. The investigators have selected
      these two populations as the represent the spectrum of solid organ transplantation: kidney
      transplant recipients are the largest transplant population, but have lower levels of
      immunosuppression and skin cancer risk. Lung transplant recipients have the highest burden of
      skin cancer and actinic keratoses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant's adverse events measuring the safety of ingenol mebutate gel 0.015%</measure>
    <time_frame>From screening to Day 57 or study early termination if applicable</time_frame>
    <description>To evaluate the safety of ingenol mebutate gel 0.015% on the face in solid organ transplant recipients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant's actinic keratosis count</measure>
    <time_frame>At screening, day 1, day 29, day 57, and study early termination if applicable.</time_frame>
    <description>To evaluate the efficacy of ingenol mebutate for reduction of actinic keratoses on the face in organ transplant recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Local Skin Response Grading Scale</measure>
    <time_frame>On day 1, day 4, day 15, day 29, day 57, and study early termination if applicable.</time_frame>
    <description>To investigate the local skin response to ingenol mebutate in organ transplant recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of life in organ transplant recipients</measure>
    <time_frame>On day 1, day 4, day 15, day 29, day 57, and study early termination if applicable.</time_frame>
    <description>To investigate the effect of topical treatment with ingenol mebutate on patient reported outcomes of pain and quality of life in organ transplant recipients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Open label treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ingenol mebutate gel 0.015%</intervention_name>
    <description>ingenol mebutate gel 0.015% to be applied on treatment area</description>
    <arm_group_label>Open label treatment</arm_group_label>
    <other_name>Picato</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults at least 18 years old.

          2. Subject must be a solid organ transplant recipient at least one year from the date of
             transplantation.

          3. Subjects must be in stable health as confirmed by medical history, per investigator
             judgement.

          4. Subjects must be able to read, sign, and understand the informed consent.

          5. Subjects have at least 4 and no more than 20 clinically typical
             (non-hyperkeratotic/hypertrophic), visible actinic keratoses in a treatment area of
             approximately 100cm2 on the face. Treatment areas will include a single cheek
             (nasofacial sulcus to tragus, malar cheekbone to jawline and avoiding the lower eyelid
             and mouth); the forehead (hairline to eyebrows, extending laterally to the root of the
             helix).

          6. Subject must be willing to forego any other treatments on the face, including
             cryotherapy, tanning bed use and excessive sun exposure while in the study.

          7. Subject is willing and able to participate in the study and to comply with all study
             requirements including concomitant medication and other treatment restrictions.

          8. If subject is a female of childbearing potential she must have a negative urine
             pregnancy test result prior to study treatment initiation and must agree to use an
             approved method of birth control while enrolled in the study.

        Exclusion Criteria:

          1. Subjects with an unstable medical condition as deemed by the clinical investigator.

          2. Subjects with a history of bone marrow or stem cell transplantation.

          3. Subjects with non-melanoma skin cancer on the face.

          4. Subjects with hyperkeratotic or hypertrophic AKs.

          5. Subjects with any dermatologic disease in the treatment area that may be exacerbated
             by the treatment proposed or that might impair the evaluation of AKs.

          6. Women who are pregnant, lactating, or planning to become pregnant during the study
             period.

          7. Subjects who have previously been treated with ingenol mebutate in study area within
             the past 8 weeks.

          8. Subjects who have used any topical prescription medications for actinic keratosis on
             the study area within 8 weeks prior to study treatment initiation.

          9. Subjects who have used any topical prescription medications for other reason on the
             study area within 4 weeks prior to study treatment initiation.

         10. Subjects who are currently participating in another clinical study or have completed
             another clinical study with an investigational drug or device on the study area within
             30 days prior to study treatment initiation.

         11. Subjects with known hypersensitivity to Picato gel or any of the inactive ingredients:
             isopropyl alcohol, hydroxyethyl cellulose, citric acid monohydrate, sodium citrate, or
             benzyl alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Arron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Kembikian, BS</last_name>
    <phone>415-353-9684</phone>
    <email>Christine.Kembikian@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Dermatology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Arron, MD, PhD</last_name>
      <phone>415-353-9684</phone>
      <email>sarah.arron@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Kembikian, BS</last_name>
      <phone>415-353-9684</phone>
      <email>christine.kembikian@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Sarah Arron</investigator_full_name>
    <investigator_title>Principal Investigator &amp; Associate Professor of Dermatology in Residence</investigator_title>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>lung transplant</keyword>
  <keyword>kidney transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data may be shared with authorized representatives of the study sponsor LEO Pharma, Inc., The University of California, FDA</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

